SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-24-031371
Filing Date
2024-04-09
Accepted
2024-04-09 09:26:15
Documents
14
Period of Report
2023-04-09
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0203558-8k_cadrenal.htm   iXBRL 8-K 29079
2 PRESS RELEASE DATE APRIL 9, 2024 ea020355801ex99-1_cadrenal.htm EX-99.1 10247
  Complete submission text file 0001213900-24-031371.txt   218859

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE cvkd-20230409.xsd EX-101.SCH 3015
4 XBRL LABEL FILE cvkd-20230409_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE cvkd-20230409_pre.xml EX-101.PRE 22359
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0203558-8k_cadrenal_htm.xml XML 3727
Mailing Address 822 A1A NORTH SUITE 300 PONTE VEDRA FL 32082
Business Address 822 A1A NORTH SUITE 300 PONTE VEDRA FL 32082 904-300-0701
Cadrenal Therapeutics, Inc. (Filer) CIK: 0001937993 (see all company filings)

IRS No.: 880860746 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41596 | Film No.: 24831382
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)